In this video, Prof. Dr. Jeroen Dekervel (University Hospitals Leuven) walks us through the results of the TOPAZ-1 study and discusses the position of durvalumab plus gemcitabine and cisplatin in the first-line treatment of biliary tract cancer.
NS ID XL-3361-Revision date 04/2023-LB